Evidence map›Paper›PMID 41860747›Full record

ReviewCurrent HIV/AIDS reports2026

Effect of Timing and Duration of ART on the Composition of HIV Reservoirs: Implications for HIV Cure Strategies.

Sukeshani Salwe, Ashwini Shete

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current HIV/AIDS reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sukeshani SalweICMR-National Institute of Translational Virology and AIDS Research (NITVAR), Plot-No. 73, G-Block, MIDC, Bhosari, Pune, 411026, Maharashtra, India.ORCID http://orcid.org/0000-0002-6924-2222
Ashwini SheteICMR-National Institute of Translational Virology and AIDS Research (NITVAR), Plot-No. 73, G-Block, MIDC, Bhosari, Pune, 411026, Maharashtra, India. ashete@nariindia.org.ORCID http://orcid.org/0000-0003-0791-2128

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewAntiretroviral therapy (ART) has transformed HIV from a fatal disease into a manageable condition by effectively suppressing viral replication. However, ART does not eradicate HIV due to the persistence of latent reservoirs-mainly replication-competent proviruses in resting CD4⁺ T cells and tissue sanctuaries-that reignite infection upon treatment interruption. This review examines how ART timing and duration influence the size, composition, and stability of the HIV reservoir. RECENT

findingsInitiating ART during acute infection limits reservoir seeding, reduces genetic diversity, and promotes faster decay of intact proviruses compared to delayed ART, which permits widespread viral integration into long-lived memory T cells and clonal expansion of replication-competent viruses. Anatomical sites such as lymph nodes, gut-associated lymphoid tissue, and the central nervous system act as critical reservoir niches. These insights are central to current HIV cure efforts, which aim for either a sterilizing cure (complete eradication of the virus) or a functional cure (durable remission without ART). Cure strategies-such as "shock-and-kill,""block-and-lock," gene editing, and immunotherapy-are being optimized based on reservoir dynamics. Evidence suggests that early-treated individuals, with smaller and more homogeneous reservoirs, are better candidates for these interventions. Although no strategy has yet achieved a cure, combining early ART with targeted interventions may improve outcomes. Understanding how ART influences reservoir dynamics is essential for developing effective HIV cure strategies. We emphasize the importance of prioritizing early-treated individuals in cure trials and advocate for integrated therapeutic approaches to achieve lasting viral remission or complete eradication.

Indexed as

Anti-HIV AgentsAnti-Retroviral AgentsHIV-1HIV InfectionsCD4-Positive T-LymphocytesDisease ReservoirsHumansProvirusesTreatment InterruptionVirus LatencyVirus ReplicationAnti-HIV AgentsAnti-Retroviral AgentsAntiretroviral TherapyEarly TreatmentHIV CureHIV ReservoirLatent InfectionViral Remission

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.